All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATL001
Therapeutic Area: Oncology Product Name: ATL001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $175.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 30, 2021
Details:
Company's lead drug, ATL001, is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens. it's lead indications, advanced non-small cell lung cancer and recurrent metastatic melanoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EP0042
Therapeutic Area: Oncology Product Name: EP0042
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Ellipses Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VAL201
Therapeutic Area: Oncology Product Name: VAL201
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: ValiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 17, 2021
Details:
ValiRx will benefit from Physiomics' expertise in modelling the effects of prostate cancer care, as well as the latest version of its Virtual TumourTM technology, which will be used to extract useful information from the additional data provided by the VAL201 clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FS118
Therapeutic Area: Oncology Product Name: FS118
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
The EPO has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
